SPPI - Double dose of Spectrum Pharma's poziotinib improves tolerability in NSCLC patients

Spectrum Pharmaceuticals (SPPI) announces data update on the safety and tolerability of twice daily ((BID)) administered poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations.These preliminary data, from Cohort 5 of the ZENITH20 clinical trial, continue to show improved tolerability with BID dosing, reduced dose interruption compared to once daily ((QD)) dosing, and a reduction in adverse events.The preliminary data also demonstrate improved anti-tumor activity with 8mg BID dosing.For the 38 patients randomized to poziotinib 16mg QD or 8mg BID, improved responses were reported in the BID arm with 31.6% of patients (6/19) reaching a partial response.The data was presented at AACR Meeting 2021.#AACR21

For further details see:

Double dose of Spectrum Pharma's poziotinib improves tolerability in NSCLC patients